Pregabalin Capsule
Product Images NDC 60760-751

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 60760-751). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

751-60 (Pregabalin 60760 751 60)

This text appears to be a label for Pregabalin capsules. The label includes information such as the quantity of capsules (60), dosage strength (75mg), manufacturer details, lot numbers, expiration dates, and storage instructions. Pregabalin is a medication used to treat nerve pain.*

FDA Label Image

Equation (Pregabain Gault Equation)

This text provides a formula for estimating creatinine clearance (CLCr) based on a person's age, weight, and serum creatinine level. It specifies different coefficients for male and female patients. The formula can be used to assess kidney function in clinical settings.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

This data presents the percentage of patients who experienced improvement in pain compared to the baseline while taking different doses of Pregabalin and a placebo. The percentages range from 0% to 100% and correspond to various dosage strengths of Pregabalin, with the highest improvement associated with the 200 mg dose three times a day.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

This text is an evaluation of the percentage of patients showing improvement in pain after taking Pregabalin 100 mg three times a day compared to a placebo. The graph shows the percentage of improvement in pain from baseline.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

This document provides information on the percentage of patients who experienced improvement in their pain levels after taking different doses of Pregabalin (300 mg two times a day, 150 mg two times a day, and 75 mg two times a day) as well as a placebo. The data is presented in a graph showing the percent improvement in pain from baseline.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

This text likely represents a chart or graph showing the percent improvement in pain from baseline for patients using different dosages of Pregabalin (200mg three times a day or 100mg three times a day) compared to a placebo. The chart indicates that more than 10% of patients saw improvement when using Pregabalin and shows the varying levels of improvement in pain from baseline, ranging from over 30% to 100%.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

This text provides information on the percentage of patients improved based on different treatments. It includes data for pregabalin at varying dosages and a placebo. Additionally, it shows the percentage improvement in pain from baseline at different levels of improvement, from over 10% to over 90%.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

This document provides data on responder rates for different studies and dosages of a medication. It includes percentages of responders at various dose levels, such as 31%, 40%, 51%, 43%, 49%, and 9%. The study shows responses to different dosing regimens, including BID (twice a day) and TID (three times a day) schedules. It also indicates statistically significant results compared to a placebo. The dosage range includes 50mg/day, 150mg/day, 300mg/day, and 600mg/day.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

This is not-usable.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

This data shows the percentage of patients who experienced improvement in pain after receiving different doses of Pregabalin (600 mg, 450 mg, and 300 mg) compared to those who received a placebo. The chart also indicates the various levels of improvement in pain from baseline, ranging from above 20% to 100%.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

This is a chart displaying estimated subjects without LIR (likely intermittent responders) for Pregabalin and Placebo over a period of 180 days. The chart shows percentages ranging from 0% to 100%. The number of subjects for each category is not available.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

This is an evaluation of the percentage of subjects improved after a 12-week period, comparing the results between Pregabalin and a Placebo. The chart shows the percentage of improvement from baseline to week 12, ranging from 0 to 100 percent.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

This information provides the percentage of subjects showing improvement from baseline to week 16 in a study comparing pregabalin with a placebo. The chart shows the percentage of subjects that improved in increments of 10%, ranging from below 10% to above 80%.*

FDA Label Image

Str (Pregabalin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.